Introduction
Patient and methods
Study design
Outcome measures
Peripheral vascular complications (PVC)
Organ procurement and transplantation
Immunosuppression
Statistical analysis
Results
Baseline characteristics
Variables | SPK (n = 101) | KTA (n = 26) | P-value |
---|---|---|---|
Donor | |||
Age, years | 24.2 ± 11.9 | 59.7 ± 17.4 | < 0.001 |
Gender | |||
Male | 60 (69.4%) | 12 (46.2%) | 0.224 |
Female | 41 (40.6%) | 14 (53.8%) | |
BMI, kg/m2 | 22.4 ± 3.1 | 25.4 ± 3.5 | < 0.001 |
Recipient | |||
Age, years | 42.9 ± 8.8 | 61.5 ± 8.6 | < 0.001 |
Gender | |||
Male | 57 (56.4%) | 21 (80.8%) | 0.023 |
Female | 44 (43.6%) | 5 (19.2%) | |
BMI, kg/m2 | 25.1 ± 4.2 | 28.6 ± 3.1 | < 0.001 |
Smokers, n | 21 (21%) | 7 (27%) | 0.501 |
Duration of IDDM, years | 26.6 ± 8.5 | 18.9 ± 8.9 | < 0.001 |
Duration of dialysis, years | 2.7 ± 2.6 | 7.4 ± 4.1 | < 0.001 |
Hypertension | |||
Yes | 87 (86.1%) | 23 (88.5%) | 0.756 |
No | 14 (13.9%) | 3 (11.5%) | |
Blood pressure, mmHg | |||
Systolic | 135 ± 17 | 141 ± 18 | 0.03 |
Diastolic | 76 ± 10 | 82 ± 11 | 0.02 |
Antihypertensive drugs, n | 2.6 ± 1.3 | 2.0 ± 1.5 | 0.046 |
Arterial obstructive disease | |||
Yes | 17 (16.8%) | 8 (30%) | 0.114 |
No | 84 (83.2%) | 18 (70%) | |
Coronary heart disease | |||
Yes | 29 (28.7%) | 19 (73.1%) | < 0.001 |
No | 71 (71.3%) | 7 (26.9%) | |
Time on waiting list, months | 10.4 ± 13.1 | 22.3 ± 28.4 | 0.012 |
Pre-emptive transplant | 22 (24.7%) | 2 (7.7%) | 0.032 |
Immunosuppression | |||
Induction therapy | |||
ALG/ATG | 74 (73.3%) | 4 (15.4%) | 0.001 |
IL2-RA | 19 (18.8%) | 12 (46.2%) | |
None | 8 (7.9%) | 10 (38.5%) | |
CNI | |||
Tacrolimus | 97 (96.0%) | 25 (96.2%) | 0.979 |
Cyclosporin | 4 (4%) | 1 (4.5%) | |
AP drug | |||
MMF | 83 (82.2%) | 22 (84.6%) | 0.002 |
SRL | 14 (13.9%) | 0 | |
Multiple | 3 (3.0%) | 0 | |
None | 1 (1%) | 4 (15.4%) |
Variables | SPK (n = 22) | KTA (n = 20) | P-value |
---|---|---|---|
Donor | |||
Age, years | 50.5 ± 4.5 | 61.7 ± 6.7 | < 0.01 |
Gender | |||
Male | 16 (72.7%) | 16 (80%) | 0.580 |
Female | 6 (27.3%) | 4 (20%) | |
BMI, kg/m2 | 27.8 ± 3.9 | 27.7 ± 2.7 | 0.884 |
Recipient | |||
Age, years | 30.7 ± 12.7 | 60.4 ± 15.8 | < 0.01 |
Gender | |||
Male | 12 (54.5%) | 8 (40%) | 0.346 |
Female | 10 (45.5%) | 12 (60%) | |
BMI, kg/m2 | 23.3 ± 2.7 | 24.8 ± 1.8 | 0.079 |
Duration of IDDM, years | 27.8 ± 7.9 | 19.2 ± 9.5 | < 0.01 |
Duration of dialysis, months | 3.8 ± 3.1 | 5.7 ± 1.9 | 0.05 |
Blood pressure, mmHg | |||
Systolic | 145 ± 10 | 148 ± 5 | 0.07 |
Diastolic | 86 ± 8 | 91 ± 5 | 0.05 |
Antihypertensive drugs, n | 3.1 ± 1.2 | 2.6 ± 1.6 | 0.237 |
Arterial obstructive disease | |||
Yes | 17 (77%) | 8 (40%) | 0.015 |
No | 5 (23%) | 12 (60%) | |
Coronary heart disease | |||
Yes | 17 (77.3%) | 19 (95%) | 0.101 |
No | 5 (22.7%) | 1 (5%) | |
Time on waiting list, months | 14.5 ± 16.9 | 16.1 ± 28.1 | 0.822 |
Pre-emptive transplant | 9 (41%) | 1 (1%) | < 0.01 |
Immunosuppression | |||
Induction therapy | |||
ALG/ATG | 15 (68.2%) | 4 (20%) | 0.006 |
IL2-RA | 5 (22.7%) | 9 (45%) | |
None | 2 (4.8%) | 7 (35%) | |
CNI | |||
Tacrolimus | 22 (100%) | 19 (95%) | 0.288 |
Cyclosporin | 0 (0%) | 1 (5%) | |
AP drug | |||
MMF | 19 (86.4%) | 17 (85%) | 0.049 |
SRL | 3 (13.6%) | 0 | |
Multiple | 0 | 0 | |
None | 0 | 3 (15%) |
Peripheral vascular diseases and complications before transplantation
Variables | Before transplantation | After transplantation | ||||
---|---|---|---|---|---|---|
SPKT (n = 101) | KTA (n = 26) | P-value | SPKT (n = 101) | KTA (n = 26) | P-value | |
Peripheral vascular diseases | ||||||
Fontaine-Classification | ||||||
I | 84 (83.2%) | 18 (69.2%) | 0.11 | 80 (79.2%) | 15 (57.7%) | 0.02 |
II a | 8 (7.9%) | 4 (15.4%) | 0.24 | 5 (5%) | 3 (11.5%) | 0.21 |
II b | 4 (4%) | 1 (3.8%) | 0.97 | 7 (6.9%) | 2 (7.7%) | 0.89 |
III | 1 (1%) | 1 (3.8%) | 0.29 | 3 (3%) | 2 (7.7%) | 0.26 |
IV | 4 (4%) | 2 (7.7%) | 0.42 | 6 (5.9%) | 4 (15.4%) | 0.11 |
Peripheral vascular complications | ||||||
Number of patients | 17 (17%) | 8 (31%) | 0.11 | 21 (21%) | 11 (42%) | 0.02 |
Ischemic Ulceration | 5 (5%) | 2 (7.7%) | 0.58 | 6 (6%) | 4 (15%) | 0.11 |
Revascularization | 9 (9%) | 4 (15%) | 0.33 | 14 (14%) | 8 (31%) | 0.04 |
Amputation | 8 (8%) | 5 (19%) | 0.08 | 12 (12%) | 6 (24%) | 0.05 |
Total PVC | 22 (22%) | 10 (38%) | 0.10 | 32 (32%) | 18 (69%) | < 0.001 |
Peripheral vascular diseases and complications after transplantation
Side of peripheral vascular disease and transplant location
Metabolic outcome
Variable | Group | Postoperative year | P- value preop vs 5-POY | P-value; SPK vs KTA, 5-POY | |||
---|---|---|---|---|---|---|---|
Preoperative | 1 | 3 | 5 | ||||
HbA1c, % | SPK | 7.8 ± 1.7 | 5.8 ± 1.2 | 5.5 ± 1.7 | 5.6 ± 0.9 | < 0.01 | < 0.01 |
KTA | 6.7 ± 0.9 | 6.4 ± 1.3 | 7.1 ± 2.1 | 7.8 ± 1.9 | < 0.01 | ||
Cholesterol, mmol/l | SPK | 5.3 ± 2.1 | 4.9 ± 1.1 | 4.6 ± 0.9 | 4.9 ± 0.8 | 0.07 | 0.99 |
KTA | 4.9 ± 1.6 | 5.3 ± 1.8 | 5.1 ± 1.2 | 5.0 ± 1.4 | 0.76 | ||
Triglyceride, mmol/l | SPK | 2.1 ± 1.2 | 1.6 ± 1.1 | 1.3 ± 1.0 | 1.4 ± 0.9 | < 0.01 | < 0.01 |
KTA | 2.6 ± 1.2 | 2.9 ± 1.7 | 2.2 ± 1.3 | 3.1 ± 1.5 | 0.08 | ||
LDL- cholesterol, mmol/l | SPK | 2.6 ± 1.4 | 2.7 ± 0.6 | 2.6 ± 1.1 | 2.5 ± 0.8 | 0.82 | 0.84 |
KTA | 2.8 ± 1.4 | 3.1 ± 1.2 | 2.8 ± 0.9 | 2.7 ± 0.8 | 0.84 | ||
HDL- cholesterol, mmol/l | SPK | 1.5 ± 0.6 | 1.4 ± 0.3 | 1.7 ± 0.5 | 1.6 ± 0.3 | 0.89 | 0.01 |
KTA | 1.2 ± 0.4 | 1.1 ± 0.5 | 1.2 ± 0.2 | 1.3 ± 0.3 | 0.67 | ||
Serum creatinine, μmol/l | SPK | 156 ± 21 | 127 ± 8 | 132 ± 10 | 135 ± 11 | 0.04 | 0.12 |
KTA | 210 ± 29 | 161 ± 15 | 178 ± 25 | 195 ± 37 | 0.09 |